New fitusiran 10 mg dose increases proportion of people with hemophilia within target antithrombin range of 15–35%

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Efficacy and safety of the antithrombin siRNA fitusiran as prophylaxis in haemophilia a and B: A systematic review and meta-analysis2025 · 1 citations
2. 2CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran2025
3. 3Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress2025
4. 4Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran2025 · 1 citations
5. 5Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)2025